CGT6297 for Cancer

This trial tests a new treatment called CGT6297 for individuals with advanced solid tumors that have a specific genetic mutation (PIK3CA). The study aims to determine the treatment's safety, its effects on the body, and its potential to shrink tumors. Participants will receive varying doses to identify the optimal amount and assess effectiveness. Suitable candidates have tumors with PIK3CA mutations and have exhausted other treatments that were ineffective or unsuitable. As a Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive it.

The trial information does not specify if you need to stop taking your current medications. However, if you are on small molecule chemotherapy, anticancer therapies, or radiotherapy, you may need to stop them within certain timeframes before starting the study drug.

A previous study showed that CGT6297 was promising in treating tumors in a breast cancer model. The drug caused noticeable tumor shrinkage at various doses in mice, suggesting potential effectiveness against certain cancers. However, this trial marks the first time CGT6297 is tested in humans, so information on human tolerance remains limited.

Researchers are excited about CGT6297 because it offers a novel approach to cancer treatment. Unlike standard therapies that might target the cancer cells directly, CGT6297 is designed to be administered orally and may work through a new mechanism of action, potentially disrupting the cancer's growth pathways more effectively. This innovative delivery method and mechanism could offer more convenience and potentially improve outcomes for patients who might not respond well to existing treatments.

Research has shown that CGT6297 may be effective against cancers with PIK3CA mutations, which are changes in a gene that can cause tumors to grow. Studies have found that CGT6297 blocks the signals that help these cancers grow. The body absorbs it well when taken as a pill. Early lab studies demonstrated its effectiveness in certain cancer types, such as mutant breast cancer, suggesting it might help slow or stop cancer growth in people. Participants in this trial will receive CGT6297 in different phases, including a dose escalation phase and a signal-seeking phase, to evaluate its effectiveness and safety.⁶⁷⁸⁹¹⁰